 |
||
|
| ||||||||||||||||||||||||||||||
|  |  Cerexa to Present at Credit Suisse First Boston Healthcare ConferencePress Release November 15, 2005 ALAMEDA, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Cerexa, Inc. (www.cerexa.com) today announced that Dennis G. Podlesak, Chief Executive Officer, will present at the Credit Suisse First Boston Annual Heal thcare Conference in Phoenix, AZ on Wednesday, November 16, 2005 at 12:00 p.m. MST (2:00 p.m. EST) at The Arizona Biltmore. Mr. Podlesak will provide a brief corporate overview and discuss the company's lead product candidate, PPI-0903. About Cerexa Cerexa, Inc., located in Alameda, California, is a biopharmaceutical company committed to developing and commercializing a growing portfolio of novel anti-infective therapies for the treatment of serious and life- threatening infections. Cerexa's lead compound is PPI-0903, a next-generation cephalosporin currently being investigated as a potential treatment for complicated skin and skin-structure infections. For additional company information, please visit www.cerexa.com. Source: Cerexa, Inc. CONTACT: Stan Abel of Cerexa, Inc., 510-747-3911, or seabel@cerexa.com; or Jane Petrino of Noonan Russo, 212-845-4274, or jane.petrino@eurorscg.com Web site: http://www.cerexa.com/
About hireCentral
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page